These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 24078271)
21. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124 [TBL] [Abstract][Full Text] [Related]
22. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR; Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529 [TBL] [Abstract][Full Text] [Related]
23. Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas. Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562 [TBL] [Abstract][Full Text] [Related]
24. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529 [TBL] [Abstract][Full Text] [Related]
25. [Clinical significance of survivin expression in peripheral T-cell lymphoma]. Xiang XJ; He YJ; Li YH; Huang H; Xu F Ai Zheng; 2006 Jun; 25(6):758-61. PubMed ID: 16764776 [TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
27. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843 [TBL] [Abstract][Full Text] [Related]
28. Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome? Pileri A; Pellegrini C; Agostinelli C; Grandi V; Patrizi A; Zinzani PL; Pimpinelli N Eur J Dermatol; 2017 Feb; 27(1):49-53. PubMed ID: 27873737 [TBL] [Abstract][Full Text] [Related]
29. Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum. Akagi T; Takahashi N; Yamaguchi K; Ishizawa K; Murai K; Tajima K; Ikeda K; Kameoka Y; Kameoka J; Ito S; Kato Y; Noji H; Shichishima T; Itoh J; Ichinohasama R; Harigae H; Ishida Y; Sawada K J Clin Exp Hematop; 2011; 51(1):29-35. PubMed ID: 21628858 [TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380 [TBL] [Abstract][Full Text] [Related]
31. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464 [TBL] [Abstract][Full Text] [Related]
32. Therapies for peripheral T-cell lymphomas. Savage KJ Hematology Am Soc Hematol Educ Program; 2011; 2011():515-24. PubMed ID: 22160083 [TBL] [Abstract][Full Text] [Related]
33. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma. Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677 [TBL] [Abstract][Full Text] [Related]
34. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Gkotzamanidou M; Papadimitriou CA Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060 [TBL] [Abstract][Full Text] [Related]
35. THE ROLE OF RADIATION THERAPY IN THE TREATMENT OF PTCL-NOS. Kriachok I; Aleksyk O; Tytorenko I; Bushuieva M; Moroz Y Probl Radiac Med Radiobiol; 2023 Dec; 28():504-512. PubMed ID: 38155144 [TBL] [Abstract][Full Text] [Related]
36. Peripheral T-cell lymphoma with gastrointestinal involvement and indolent T-lymphoproliferative disorders of the gastrointestinal tract. Kohri M; Tsukasaki K; Akuzawa Y; Tanae K; Takahashi N; Saeki T; Okamura D; Ishikawa M; Maeda T; Kawai N; Matsuda A; Arai E; Arai S; Asou N Leuk Res; 2020 Apr; 91():106336. PubMed ID: 32151888 [TBL] [Abstract][Full Text] [Related]
37. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. López-Guillermo A; Cid J; Salar A; López A; Montalbán C; Castrillo JM; González M; Ribera JM; Brunet S; García-Conde J; Fernández de Sevilla A; Bosch F; Montserrat E Ann Oncol; 1998 Aug; 9(8):849-55. PubMed ID: 9789607 [TBL] [Abstract][Full Text] [Related]
38. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]. Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720 [TBL] [Abstract][Full Text] [Related]
39. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma. Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886 [TBL] [Abstract][Full Text] [Related]
40. Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance. Hapgood G; Latimer M; Lee ST; Kuss B; Lade S; Tobin JWD; Purtill D; Campbell BA; Prince HM; Hawkes EA; Shortt J; Radeski D Intern Med J; 2022 Oct; 52(10):1806-1817. PubMed ID: 34668281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]